Brand vs Compounded GLP-1 (2026): $349 Wegovy vs $149 Compound — Legal Status + Safety

Verified April 2026: Brand-name Wegovy costs $349/month through NovoCare, Zepbound costs $299-449/month through LillyDirect, and compounded semaglutide has been federally banned since April 22, 2025. Compounded tirzepatide remains legal under narrow medical-necessity exemptions and starts at $149/month through Enhance MD for compounded tirzepatide or $115/month through Enhance MD for compounded semaglutide. The $1,000-vs-$150 arbitrage that defined the 2023-2024 compound market no longer exists — brand prices dropped 70% and compounding enforcement ended shortage-based access.

Quick answer by situation:

• •Want the cheapest legal option today: Enhance MD at $115/month compounded semaglutide (narrow medical-necessity) or Enhance MD at $149/month compounded tirzepatide — both FDA-registered pharmacies.
• •Want FDA-approved brand at the lowest price: NovoCare Wegovy $349/month or LillyDirect Zepbound $299/month for the starter 2.5mg vial.
• •Medicare beneficiary: Coverage launches July 2026 at $50/month copay — see the Medicare Part D GLP-1 guide.
• •Still on compounded semaglutide: It's been enforced against since April 2025. See the compounded crackdown guide for switch options.

This guide breaks down the four-part decision — legality, safety, cost, and weight loss outcomes — using FDA enforcement timelines, current provider pricing, and clinical trial data. Verify any provider with our FDA Safety Checker or compare all 48 telehealth programs by cost and score.

What Are Compounded GLP-1s?

Compounded GLP-1 medications are custom-mixed formulations prepared by compounding pharmacies using the base active ingredient (semaglutide or tirzepatide). They are NOT FDA-approved products and they are NOT generics. There are two types of compounding pharmacies:

• •503A pharmacies: Traditional state-licensed compounding pharmacies that fill patient-specific prescriptions
• •503B outsourcing facilities: Larger-scale facilities registered with the FDA that can produce compounded drugs without patient-specific prescriptions

Are Compounded GLP-1s Still Legal in 2026?

Under federal law, compounding pharmacies can only produce copies of commercially available drugs when those drugs are in shortage. Here's what happened:

• •February 21, 2025: FDA removes semaglutide from the drug shortage list
• •April 22, 2025: Enforcement deadline for 503A (state-licensed) pharmacies to stop compounding semaglutide
• •May 22, 2025: Enforcement deadline for 503B outsourcing facilities
• •September 2025: FDA issues 50+ warning letters to compounders for false/misleading marketing claims
• •February 2026: FDA announces seizure and injunction powers against non-compliant compounders
• •April 30, 2026: FDA proposes permanent exclusion of semaglutide, tirzepatide, and liraglutide from the 503B bulk drug substances list (Federal Register publication May 1, 2026). FDA found no demonstrated clinical need for outsourcing facilities to compound these drugs from bulk substances. Comment period runs through June 29, 2026 before any final rule.

Tirzepatide (Mounjaro/Zepbound) compounding enforcement ended even earlier — March 2025. A Texas federal judge upheld the ban.

Are Compounded GLP-1s Safe?

The FDA has documented significant safety issues with compounded GLP-1 products:

• •520+ adverse event reports for compounded semaglutide as of April 2025
• •480+ adverse event reports for compounded tirzepatide
• •Reports of patients self-administering 5-20x the intended dose due to vial confusion
• •Impurities found up to 24% in some tested compounded products
• •Fraudulent products with fake pharmacy labels identified by regulators
• •Multiple hospitalizations documented

Brand vs Compounded: Direct Comparison

What This Means for You in 2026

The compounded GLP-1 market hasn't disappeared entirely, but it has shrunk significantly according to the FDA's compounding policy update. Some providers still offer compounded options under narrow medical-necessity exemptions (e.g., documented allergy to inactive ingredients in brand products). Compounding for cost savings alone is not a legally valid basis. Notably, Embody offers compounded tirzepatide in an oral gum format — an alternative for patients who cannot tolerate injections, starting at $149 for the first month.

The good news: brand-name prices have dropped substantially. Novo Nordisk now offers Wegovy/Ozempic at $349/month through self-pay programs, and Eli Lilly sells Zepbound vials for $299-449/month through LillyDirect. Medicare coverage at $50/month copay launches in July 2026. These changes narrow the price gap considerably.

If you were on compounded semaglutide specifically, the FDA ban has already taken effect. See our detailed compounded semaglutide crackdown guide for a full breakdown of your options — including compounded tirzepatide, which remains legal and starts at $149/month.

The Lawsuit Landscape

Both major GLP-1 manufacturers have been aggressively protecting their products:

• •Novo Nordisk filed 130+ lawsuits against compounders across 40 states
• •Novo Nordisk sued Hims & Hers in February 2026; they settled in March 2026 with a partnership deal for Hims to distribute branded Wegovy
• •Eli Lilly sued multiple telehealth companies and compounders
• •Strive Pharmacy filed an antitrust countersuit against both companies in January 2026